|
Bermuda
(州或其他管轄範圍 成立公司或組織) |
| |
98-1327726
(I.R.S. Employer 識別碼) |
|
|
Copies to:
|
| |||
|
Johan V. Brigham
Nathan Ajiashvili Latham & Watkins LLP 200 Clarendon Street, 27th Floor Boston, Massachusetts 02116 (617) 948-6000 |
| |
Alan Dickson
Conyers Dill&Pearman Limited Clarendon House 2 Church Street PO Box HM 666 Hamilton, HM CX, Bermuda +1 (441) 295-1422 |
|
|
Large accelerated filer ☐
|
| |
Accelerated filer ☐
|
| |
Non-accelerated filer
|
| |
較小的報告公司
Emerging growth company ☐
|
|
|
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
|
TRADEMARKS
|
| | | | 1 | | |
|
您可以在這裏找到更多信息;通過引用合併
|
| | | | 2 | | |
|
THE COMPANY
|
| | | | 4 | | |
|
RISK FACTORS
|
| | | | 5 | | |
|
USE OF PROCEEDS
|
| | | | 6 | | |
|
股本説明
|
| | | | 7 | | |
|
債務證券説明
|
| | | | 13 | | |
|
認股權證説明
|
| | | | 20 | | |
|
DESCRIPTION OF UNITS
|
| | | | 21 | | |
|
GLOBAL SECURITIES
|
| | | | 22 | | |
|
PLAN OF DISTRIBUTION
|
| | | | 26 | | |
|
LEGAL MATTERS
|
| | | | 28 | | |
|
EXPERTS
|
| | | | 28 | | |
|
SEC registration fee
|
| | | $ | 16,257(1) | | |
|
FINRA filing fee
|
| | | $ | (2) | | |
|
Printing expenses
|
| | | $ | (2) | | |
|
Legal fees and expenses
|
| | | $ | (2) | | |
|
會計費和費用
|
| | | $ | (2) | | |
|
藍天資格費和費用
|
| | | $ | (2) | | |
|
轉會代理費和費用
|
| | | $ | (2) | | |
|
託管費和開支
|
| | | $ | (2) | | |
|
託管費和費用
|
| | | $ | (2) | | |
|
授權證代理費和費用
|
| | | $ | (2) | | |
|
Miscellaneous
|
| | | $ | (2) | | |
|
Total
|
| | | $ | (2) | | |
|
Exhibit
Number |
| |
Exhibit Description
|
| |
引用註冊成立
|
| ||||||
|
Form
|
| |
Exhibit
Number |
| |
Filing
Date |
| ||||||
| 3.1 | | |
Kiniksa製藥有限公司協會備忘錄
|
| |
S-1
|
| |
3.1
|
| |
4/27/18
|
|
| 3.2 | | |
修訂和重新修訂Kiniksa製藥有限公司的公司章程
|
| |
8-K
|
| |
3.1
|
| |
5/29/18
|
|
| 4.1 | | |
證明A類普通股的股票證書樣本
|
| |
S-1/A
|
| |
4.1
|
| |
5/14/18
|
|
| 4.2 | | |
第二次修訂和重新簽署的《投資者權利協議》,日期為2018年2月9日
|
| |
S-1
|
| |
4.2
|
| |
4/27/18
|
|
| 4.3* | | |
Form of Indenture
|
| | | | | | | | | |
| 4.4** | | | Form of Note | | | | | | | | | | |
| 4.5** | | | Form of Warrant | | | | | | | | | | |
| 4.6** | | | 保修協議格式 | | | | | | | | | | |
| 4.7** | | | 單位協議格式 | | | | | | | | | | |
| 5.1* | | | 註冊人的百慕大律師Conyers Dill&Pearman Limited對A類普通股和優先股的有效性的意見 | | | | | | | | | | |
| 5.2* | | |
註冊人的美國律師Latham&Watkins LLP對債務證券、權證和單位的有效性的意見
|
| | | | | | | | | |
| 23.1* | | |
註冊人的百慕大律師事務所Conyers Dill&Pearman Limited同意(見附件5.1)
|
| | | | | | | | | |
| 23.2* | | |
註冊人的美國律師Latham&Watkins LLP同意(包括在附件5.2中)
|
| | | | | | | | | |
| 23.3* | | |
獨立註冊會計師事務所普華永道同意
|
| | | | | | | | | |
| 24.1* | | |
授權書(參考本文件簽名頁合併)
|
| | | | | | | | | |
| 25.1*** | | | 根據修訂後的1939年《信託契約法》,採用表格T-1的資格聲明 | | | | | | | | | | |
| 107* | | |
Filing Fee Table
|
| | | | | | | | | |
| | | | KINIKSA製藥有限公司 | | |||
| | | | By: | | |
/s/ Sanj K. Patel
Sanj K. Patel
首席執行官兼董事會主席 |
|
|
Signature
|
| |
Title
|
| |
Date
|
|
|
/s/ Sanj K. Patel
Sanj K. Patel
|
| |
首席執行官兼董事會主席
(首席執行官) |
| |
May 6, 2022
|
|
|
/s/ Mark Ragosa
Mark Ragosa
|
| |
Chief Financial Officer
(首席財務官) |
| |
May 6, 2022
|
|
|
/s/ Michael R. Megna
Michael R. Megna
|
| |
集團副總裁、財務兼首席會計官
(首席會計官) |
| |
May 6, 2022
|
|
|
/s/ Felix J. Baker
Felix J. Baker
|
| |
獨立董事首席執行官
|
| |
May 6, 2022
|
|
|
/s/ Stephen R. Biggar
Stephen R. Biggar
|
| |
Director
|
| |
May 6, 2022
|
|
|
/s/ G. Bradley Cole
G. Bradley Cole
|
| |
Director
|
| |
May 6, 2022
|
|
|
Signature
|
| |
Title
|
| |
Date
|
|
|
/s/ Richard S. Levy
Richard S. Levy
|
| |
Director
|
| |
May 6, 2022
|
|
|
/s/ Thomas R. Malley
Thomas R. Malley
|
| |
Director
|
| |
May 6, 2022
|
|
|
/s/ Tracey L. McCain
Tracey L. McCain
|
| |
Director
|
| |
May 6, 2022
|
|
|
/s/ Kimberly J. Popovits
Kimberly J. Popovits
|
| |
Director
|
| |
May 6, 2022
|
|
|
/s/ Barry D. Quart
Barry D. Quart
|
| |
Director
|
| |
May 6, 2022
|
|
| | | | KINIKSA製藥公司 | | |||
| | | | By: | | |
/s/ Sanj K. Patel
Sanj K. Patel
首席執行官 |
|